References
- The Drug Enforcement Administration. National drug threat assessment 2019. December 2019 edn. Springfield, VA: U.S. Drug Enforcement Administration; 2019.
- Muñoz-Vahos CH, Herrera-Uribe S, Arbeláez-Cortés Á, et al. Clinical profile of levamisole-adulterated cocaine-induced vasculitis/vasculopathy: a 30-case series. J Clin Rheumatol. 2019;25(3):e16–e26.
- Marquez J, Aguirre L, Muñoz C, et al. Cocaine-levamisole-induced vasculitis/vasculopathy syndrome. Curr Rheumatol Rep. 2017;19(6):36.
- Midthun KM, Nelson LS, Logan BK. Levamisole-a toxic adulterant in illicit drug preparations: a Review. Ther Drug Monit. 2021;43(2):221–228.
- Bolognia J, Schaffer J, Cerroni L. Chapter 21: Drug reactions. In: Dermatology. Philadelphia: Elsevier; 2018. pp. 357–358.